Age and Gender as Determinants of Anxiety in Functional Bowel Disorders: Impact on Quality of Life and the Need for Tailored Guidelines

Vol. 31, Issue 3 (September 2026)

Atteyat A. Semeya, MD
Consultant of Hepatogastroenterology
Benha Teaching Hospital
Benha, Egypt

 

Introduction

Functional bowel disorders (FBDs)—including irritable bowel syndrome (IBS), functional dyspepsia, functional constipation, and functional diarrhea—affect up to 40% of the global population and account for a substantial proportion of gastroenterological consultations worldwide.¹ A well-established but frequently underappreciated aspect of these conditions is their bidirectional relationship with anxiety disorders, which occur in 30–60% of affected patients.²

What remains poorly addressed in current clinical practice—and conspicuously absent from existing guidelines—is the extent to which age and gender shape this comorbidity. Both biological sex and age act as powerful modulators of gut-brain axis function, visceral sensitivity, and psychopathological vulnerability. This expert opinion summarizes the current evidence, highlights the impact on health-related quality of life (HRQoL), and argues that the field urgently requires sex- and age-stratified clinical recommendations.

Gender Differences in FBD-Related Anxiety

Women are diagnosed with IBS at approximately twice the rate of men, and comorbid anxiety disorders follow a similar pattern: prevalence approaches 50–65% in female FBD patients compared with 20–35% in males.³ This disparity is not merely a reflection of greater healthcare-seeking behavior—it has a robust neurobiological basis.

Estrogen and progesterone exert significant modulatory effects on serotonergic neurotransmission and hypothalamic-pituitary-adrenal (HPA) axis reactivity, two systems central to both gut motility and anxiety regulation. Women demonstrate greater amygdalar reactivity to visceral stimuli and heightened interoceptive sensitivity compared with men.⁴ Hormonal transitions—particularly the perimenopausal period—are associated with peak comorbidity burden, as estrogen withdrawal amplifies both visceral symptoms and anxiety.

In men, the clinical picture is often obscured by sociocultural expectations of emotional stoicism, leading to systematic underreporting of anxiety symptoms and diagnostic delay. Emerging evidence suggests that hypogonadism in aging men may unmask anxiety presentations more commonly associated with female FBD patients, blurring traditional sex-based symptom boundaries.

Transgender and gender-diverse individuals represent a significantly understudied population in this context. The elevated baseline prevalence of anxiety disorders in this group, combined with the physiological effects of gender-affirming hormone therapy on gut-brain signaling, warrants dedicated clinical attention and research investment.

Age-Related Vulnerability Across the Lifespan

The intersection of FBDs and anxiety is not static across the lifespan. Table 1 summarizes the key clinical characteristics across age groups.

In children and adolescents, FBDs—particularly functional abdominal pain—are intimately linked to state and trait anxiety. Longitudinal data confirm that childhood anxiety predicts adult IBS, establishing a developmental trajectory that demands early identification and intervention.⁵ Female adolescents bear a disproportionate burden post-menarche, with FBD-anxiety comorbidity escalating sharply after pubertal onset.

Older adults with FBDs represent an especially underserved group. Anxiety in this population frequently presents as somatic equivalents—excessive health monitoring, fatigue, and insomnia—rather than the cognitive and affective features emphasized in DSM-5 criteria. This atypical presentation leads to systematic underdiagnosis. Compounding this, pharmacological management is complicated by polypharmacy, altered drug metabolism, and heightened sensitivity to adverse effects of antidepressants including fall risk and QTc prolongation.

Impact on Health-Related Quality of Life

The co-occurrence of anxiety in FBD patients does not simply add to symptom burden—it multiplies it. Systematic reviews consistently demonstrate that anxiety comorbidity reduces both disease-specific quality of life (IBS-QoL, FDDQL) and generic HRQoL (SF-36, EQ-5D) to a greater extent than either condition alone.⁶ Work productivity loss and healthcare utilization are substantially amplified.

The HRQoL profile differs meaningfully by demographic group. Women with comorbid FBDs and anxiety report disproportionate impairment in emotional functioning, social participation, and sexual health—domains frequently omitted from routine clinical assessments. Adolescent patients suffer academic underperformance and peer relationship disruption. Older adults experience the most severe overall HRQoL decrements, with loss of independence and heightened risk of depression, frailty, and social withdrawal.

These demographic disparities underscore the inadequacy of a single HRQoL measurement approach across all FBD-anxiety patients. Clinicians should select patient-reported outcome measures appropriate to the patient's age and sex and should explicitly inquire about domains—such as sexual health and occupational functioning—that standard instruments may not capture.

Gaps in Current Guidelines and the Case for Stratified Recommendations

A review of major guidelines—from the American College of Gastroenterology (ACG), the Rome Foundation, and the European Society of Neurogastroenterology and Motility (ESNM)—reveals a largely undifferentiated approach to psychiatric comorbidity in FBDs.⁷ Where anxiety is acknowledged, it typically serves as a modifier of symptom severity rather than an independent diagnostic and therapeutic target.

Crucially, existing guidelines contain no sex-stratified recommendations for screening intervals, pharmacological choices, or psychological intervention modalities. Age-related adjustments are confined to broad pediatric-adult distinctions, with no specific guidance for adolescents, perimenopausal women, or older adults. This demographic agnosticism is scientifically untenable given the evidence reviewed above and likely contributes to suboptimal patient outcomes at scale.

Recommended Practice Improvements

• Mandatory integration of validated, age-appropriate anxiety screening into FBD diagnostic workup (GAD-7 for adults; SCARED for children; Geriatric Anxiety Inventory for older adults).
• Sex-stratified pharmacological guidance—particularly for antidepressant use—accounting for estrogen-mediated CYP450 enzyme variability and geriatric pharmacokinetic adjustments.
• Recognition of perimenopausal status as a high-risk period requiring proactive anxiety assessment in women with FBDs.
• Gender-sensitive communication strategies to reduce underreporting in male and gender-nonconforming patients.
• Development of demographically specific patient-reported outcome measures for the FBD-anxiety comorbidity.

Conclusion

Age and gender are not peripheral variables in the clinical landscape of FBD-associated anxiety—they are central determinants of disease expression, treatment response, and quality of life impact. The current one-size-fits-all approach embedded in existing guidelines is inconsistent with a growing body of mechanistic, epidemiological, and clinical evidence.

We call upon professional gastroenterological and psychiatric societies to prioritize the development of sex- and age-stratified recommendations for screening, pharmacotherapy, and psychological management in FBD patients with anxiety comorbidity. Such an approach represents both a scientific imperative and a commitment to equitable, patient-centered care.

References

1. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV. Gastroenterology. 2016;150(6):1262–1279.
2. Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651–660.
3. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders. Gastroenterology. 2002;122(4):1140–1156.
4. Mayer EA, Labus JS, Tillisch K, Cole SW, Baldi P. Towards a systems view of IBS. Nat Rev Gastroenterol Hepatol. 2015;12(10):592–605.
5. Shelby GD, Shirkey KC, Sherman AL, et al. Functional abdominal pain in childhood and long-term vulnerability to anxiety disorders. Pediatrics. 2013;132(3):475–482.
6. Ballou S, Keefer L. Psychological interventions for irritable bowel syndrome and inflammatory bowel diseases. Clin Transl Gastroenterol. 2017;8(1):e214.
7. Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150(6):1393–1407.
8. Heitkemper MM, Jarrett ME. Pattern of gastrointestinal and somatic symptoms across the menstrual cycle. Gastroenterology. 1992;102(2):505–513.
9. Simrén M, Törnblom H, Palsson OS, et al. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders. Gut. 2018;67(2):255–262.
10. Keefer L, Palsson OS, Pandolfino JE. Best Practice Update: Incorporating Psychogastroenterology into Management of Digestive Disorders. Gastroenterology. 2018;154(5):1249–1257.